MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to oncotelic...
-$2,193,776
Net loss
attributable to...
-$45,500
Net loss before
non-controlling interests
-$2,239,276
Loss from operations
-$1,853,385
Total other expense
-$385,891
Total operating
expenses
$1,853,385
Interest expense, net
$295,811
Change in fair value of
derivative on debt
-$90,080
General and
administrative
$1,852,590
Research and development
$795
Back
Back
Income Statement
source: myfinsight.com
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)